- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
PAPILLON Trial Insights: ESMO 2023
Patrick Forde, MBBCh, discusses advances in EGFR Exon 20 insertion-mutated NSCLC.
EP: 1.CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC
EP: 2.Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy
EP: 3.Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023
EP: 4.Lessons from LIBRETTO-431 Trial in RET+ NSCLC
EP: 5.PAPILLON Trial Insights: ESMO 2023
EP: 6.Innovations Needed and Future Directions in Treatment of NSCLC
This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.
Forde discusses results from the PAPILLON trial (NCT04538664) of amivantamab, a bispecific antibody targeting EGFR and MET in EGFR exon 20 insertion–mutated non–small cell lung cancer (NSCLC). EGFR exon 20 insertions occur in about 2% 3% of NSCLC cases, predominantly nonsquamous histology. Amivantamab is approved in previously treated EGFR exon 20 NSCLC.
The PAPILLON trial compared amivantamab plus chemotherapy with chemotherapy alone in untreated advanced EGFR exon 20 NSCLC. Amivantamab plus chemotherapy significantly improved progression-free survival with an HR of 0.395 vs chemotherapy alone. Objective response rate increased from 47% with chemotherapy to 73% with amivantamab plus chemotherapy. There was also an early overall survival trend favoring amivantamab.
Forde states these results support up-front use of amivantamab plus chemotherapy for EGFR exon 20 advanced NSCLC. He notes amivantamab can cause infusion reactions and increased venous thromboembolism risk to monitor. Overall, this regimen meaningfully improves outcomes for patients with this rare EGFR alteration.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Study Highlights BMP7 as a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More
